Aprea Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
APRE Nasdaq 8731 https://www.aprea.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aprea Therapeutics Inc

Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business Operations - Mar 30th, 2023 8:05 pm
Aprea Therapeutics Announces Presentation of Preclinical Data on Pipeline Programs at the AACR 2023 Annual Meeting - Mar 16th, 2023 12:00 pm
Aprea Therapeutics to Present at Oppenheimer’s 33rd Annual Healthcare Conference - Mar 7th, 2023 1:00 pm
Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - Mar 1st, 2023 9:05 pm
Aprea Therapeutics Announces Closing of $5.5 Million Underwritten Public Offering of Common Stock - Feb 27th, 2023 9:05 pm
Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common Stock - Feb 23rd, 2023 1:41 am
Aprea Therapeutics Announces Proposed Public Offering of Common Stock - Feb 22nd, 2023 9:05 pm
Aprea Therapeutics Announces Phase II SBIR Award from the National Cancer Institute (NCI) - Feb 15th, 2023 1:00 pm
Aprea Therapeutics Announces One-for-Twenty Reverse Stock Split - Feb 13th, 2023 12:00 pm
Aprea Therapeutics Appoints John Hamill as Chief Financial Officer - Jan 30th, 2023 1:00 pm
Aprea Therapeutics to Participate in 6th Annual DNA Damage and Response (DDR) Inhibitors Summit - Jan 19th, 2023 1:00 pm
Aprea (APRE) Rises on Advancing Lead Drug to Clinical Studies - Jan 12th, 2023 2:56 pm
Aprea Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of Oral ATR Inhibitor ATRN-119 for the Treatment of Advanced Solid Tumors - Jan 11th, 2023 1:00 pm
Aprea Therapeutics Reports Third Quarter 2022 Financial Results and Provides Update on Business Operations - Nov 9th, 2022 9:15 pm
Aprea Therapeutics Announces Poster Presentation at the 2022 Rivkin Center and American Association for Cancer (AACR) Virtual Ovarian Cancer Research Seminar Series - Sep 22nd, 2022 10:00 pm
Aprea Therapeutics to Participate in the 2022 H.C. Wainwright Global Investment Conference - Sep 8th, 2022 12:00 pm
Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations - Aug 11th, 2022 8:15 pm
Aprea Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Conference - Aug 2nd, 2022 12:00 pm
Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results - May 16th, 2022 1:21 pm